


# STEROID RECEPTORS IN OVARIAN NEOPLASMS

A Thesis  
Submitted for the partial fulfilment of the  
M.D., Degree in  
Gynecology and Obstetrics

By  
*Hassan Tawfik Hassan Khairy*  
M.B., B.Ch., M.Sc. Gyn. & Obst.



Under Supervision of

*Prof. Dr. Khalil Ismail El-Lamei*  
Professor and Head of Gynecology and Obstetrics Department




*Dr. Mahmoud Youssef Abdalla*  
Assistant Professor of Gynecology and Obstetrics

616.99265  
H.T.

*Prof. Dr. Aly Khalifa*  
Professor of Biochemistry

48116

*Dr. Sanaa Eissa*  
Lecturer of Biochemistry



Faculty of Medicine  
Ain Shams University  
1994





### ACKNOWLEDGEMENT

I wish to express my deep thanks and gratitude to my Professor Dr. Khalil Ismail El-Lamei Professor and head of Gynecology and Obstetrics, Faculty of Medicine, Ain Shams University, for giving me the privilege and the honour of working under his supervision.

I would like also to express my deep gratitude and thanks to Dr. Mahmoud Youssef Abdalla Assistant Professor of Gynecology and Obstetrics, Faculty of Medicine, Ain Shams University, for his kind supervision and energetic help in following the details to ensure that this work would reach an updated level.

I am also sincerely thankful to Professor Dr. Ali Khalifa Professor of Biochemistry, Faculty of Medicine, Ain Shams University and Dr. Sanaa Eissa Lecturer of Biochemistry, Faculty of Medicine, Ain Shams University, for their continuous advice, encouragement, meticulous follow up of the practical part of this work and for the financial support by the Oncology Diagnostic Unit.

Lastly, I would like also to express my great thanks to Dr. Ragaa Amin Fawzy Assistant Professor of Pathology, Faculty of Medicine, Ain Shams University for her meticulous pathological evaluation of the specimens included in this study.

### ABBREVIATIONS

AR	Androgen receptors
cAMP	Cyclic adenosine monophosphate
DCCA	Dextran coated charcoal analysis
DNA	Deoxyribonucleic acid
E2	Estradiol
EGF	Epidermal growth factor
EGF-R	Epidermal growth factor receptors
EIA	Enzyme immunoassay
ER	Estrogen receptors
ER / PR	Both ER and PR
f mole	Femto mole
FSH	Follicle-stimulating hormone
GnRH	Gonadotropin - releasing hormone
GR	Glucocorticoid receptors
hMG	Human menopausal gonadotropin
IGF	Insulin like growth factor
LH	Luteinizing hormone
LN	Lymph node
MPA	Medroxy progesterone acetate
MR	Mineralocorticoid receptors
mRNA	Messenger ribonucleic acid
P	Probability
PR	Progesterone receptors
SD	Standard deviation
SDGA	Sucrose density gradient analysis
SHR	Steroid hormone receptors
TGF	Transforming growth factor
TR	Testosterone receptors

## LIST OF TABLES AND FIGURES

	Page
Table (1) shows the mean age, menopausal status, ER concentration and positivity, PR concentration and positivity, ER / PR positivity and mean preoperative CA125 levels in patients with benign and malignant ovarian tumours.....	131
Table (2) shows ER, PR and ER / PR positivities in different pathological types of benign ovarian tumours.....	132
Table (3) shows ER concentration and ER positivity in premenopausal and postmenopausal patients suffering from malignant ovarian tumours.....	133
Table (4) shows the mean, standard deviation, range of ER concentration and positivity in different pathological types of malignant common epithelial ovarian tumours.....	134
Table (5) shows the mean, standard deviation, range of ER concentration and positivity in different grades of malignant common epithelial tumours.....	135
Table (6) shows PR concentration and positivity in premenopausal and postmenopausal patients with malignant ovarian tumours.....	138
Table (7) shows the mean, standard deviation, range of PR concentration and positivity in different pathological types of malignant common epithelial ovarian tumours.....	139
Table (8) shows the mean, standard deviation, range of PR concentration and positivity in different grades of malignant common epithelial tumours.....	140
Table (9) shows ER / PR positivity and the menopausal status in patients with malignant ovarian tumours.....	142
Table (10) shows ER / PR positivity in different pathological types of malignant common epithelial ovarian tumours.....	143
Table (11) shows ER / PR positivity and negativity among different pathological grades of malignant common epithelial tumours.....	144

Table (12) shows ER, PR and ER / PR positivities and patient's age in patients with malignant ovarian tumours.....	146
Table (13) shows ER, PR and ER / PR positivities and preoperative CA125 levels in patients with malignant ovarian tumours.....	147
Table (14) shows ER, PR and ER / PR positivities and L.N. metastasis in patients with malignant ovarian tumours.....	148
Table (15) shows the number and percentage of patients with no evidence of residual disease at 12 months follow up after surgery.....	150
Table (16) shows the number and percentage of patients with no evidence of residual disease for up to 24 months following surgery and patients who showed evidence of residual disease in less than this duration.....	152
Table (17) shows ER, PR and ER / PR positivities and disease free intervals in patients who showed evidence of residual disease.....	155
Table (18) shows the relation between the disease free interval in patients who showed evidence of residual disease with menopausal status, pathological types, histological grades and L.N. metastasis.....	158
Table (19) shows the disease free intervals in six patients all had malignant serous tumours, grade 2, stage III disease and showed evidence of residual disease.....	160
Table (20) shows collective data for all studied patients with benign ovarian tumours.....	161
Table (21) shows collective data for all studied patients with malignant ovarian tumours.....	162

Fig. (1) shows the mechanism of action of steroid and thyroid hormones. H, hormone; R, receptor.....	22
Fig. (2) shows the structure of human glucocorticoid, mineralocorticoid, and estrogen receptors.....	24
Fig. (3) shows the correlation between ER concentration and the disease free intervals in patients who showed evidence of residual malignant ovarian tumours.....	153
Fig. (4) shows the correlation between PR concentration and the disease free intervals in patients who showed evidence of residual malignant ovarian tumours.....	154



## CONTENTS

	Page
Introduction.....	1
Aim of the Work.....	3
Review of Literature.....	4
* Physiology of steroid hormone receptors.....	4
* Steroid receptors in normal endometrium.....	32
* Steroid hormone receptors in normal human ovarian tissue.....	39
* Steroid receptors assay.....	41
* Pathology and staging of ovarian tumours.....	49
* Steroid receptors in ovarian tumours.....	68
* Steroid hormone receptors in other gynaecological malignancies.....	97
* Endocrine therapy in ovarian cancer.....	100
Material and Methods.....	114
Results.....	128
Discussion.....	163
Summary and conclusion.....	181
References.....	185
Arabic Summary	

# INTRODUCTION

### INTRODUCTION

The prognosis for women with ovarian carcinoma is poor because of late diagnosis. Early symptoms are lacking and by the time symptoms do appear, in 60-70% of cases the disease has already spread all over the peritoneal cavity (Stage III). The 5 year survival rate is less than 20% in stages III and IV compared with almost 80% in patients with stage I disease (FIGO, 1979). To improve results, a method for early detection of the disease together with an effective chemotherapeutic drugs are imperative. Unfortunately the response of the tumours to the currently used chemotherapeutic drugs is still erratic with no reliable indicator to know the response of the patient. Further, till today there are only a few ways of following the course of the disease and the effectiveness of the treatment (Agarwal et al., 1987).

Various tumour markers have not hitherto proved helpful in clinical use, some monoclonal antibodies are still on trial, but their usefulness in the early detection and in the prediction of the prognosis of the disease has yet to be proved.

Both benign and malignant ovarian neoplasms have been recently shown to contain ER and PR receptor proteins (Seveldt et al., 1990 and Rose et al., 1990). The presence

of these receptors in ovarian malignancy, like the breast and endometrial carcinomas suggest that the ovarian tumours may be potentially hormonal dependent (Agarwal et al., 1987). However the biological importance of these receptors, their possible relation to the natural history of ovarian neoplasms and their possible prognostic values are not yet fully understood.

The prognostic significance of ER and PR had been defined most clearly in patients with breast and endometrial cancer (McGuire et al., 1983; Ehrlich et al., 1981), and these steroid hormone receptors had been shown to be a reliable markers in these cancers for selection of patients who will benefit from endocrinal therapy (Martin et al., 1979; McGuire, 1979). It therefore seems reasonable to suggest that the pattern of steroid hormone receptors in ovarian carcinoma may have a similar prognostic value and a possible clinical and therapeutic benefits (Al-Timimi et al., 1985). If this does indeed turn out to be the case, then hormonal treatment may be used as a first line therapy in malignant ovarian tumours following proper cytoreductive surgery and this may improve the survival of patients suffering from ovarian cancer, with fewer side effects compared with the traditionally used cytotoxic chemotherapy.

---

# **AIM OF THE WORK**

### AIM OF THE WORK

In view of the considerable controversy regarding the presence or absence of steroid hormone receptors in different types of benign and malignant ovarian tumours, the first objective of the present study is an attempt to throw light upon this issue.

The second objective in this study is to find out the correlation between the steroid hormone receptors status and the clinical data of the patients, pathological types and grading of different ovarian tumours.

The third objective is to evaluate the possible prognostic significance of steroid hormone receptors status in patients suffering from ovarian cancer.

# **REVIEW OF LITERATURE**